Arp2/3 inhibition has recently garnered more attention as it has been associated with attenuation of cancer progression, neurotoxic effects during drug abuse, and pathogen invasion of host cells.
Given recent plans to introduce Dnmt and HDAC inhibitors as novel cancer treatments, these findings regarding the potential for Dnmt and HDAC inhibitors to enhance expression of AID and iNOS, resulting in further cancer progression, might be taken into consideration.
The molecular pathway that subverts CSR to mediate trans-chromosomal joining of Myc and Smu (translocation origin) and secondary modification of Myc-Igh junctions (translocation "remodeling") has not been elucidated, but recent evidence indicates that it includes CSR factors, such as the activation-induced cytidine deaminase (AID), that may also be involved in the ongoing neoplastic progression of the translocation-bearing tumor precursor.